Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Ionis Pharmaceuticals stock in Canada | $37.25

Own Ionis Pharmaceuticals shares in just a few minutes.

Ionis Pharmaceuticals, Inc
NASDAQ: IONS - USD
BIOTECHNOLOGY
$38.03
+$0.54 (+1.44%)

Ionis Pharmaceuticals is a biotechnology business based in the US. Ionis Pharmaceuticals stocks (IONS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $37.25 – an increase of 5.58% over the previous week. Ionis Pharmaceuticals employs 757 staff and has a trailing 12-month revenue of around $707.5 million.

How to buy Ionis Pharmaceuticals stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: IONS in this case.
  5. Research Ionis Pharmaceuticals stocks. The platform should provide the latest information available.
  6. Buy your Ionis Pharmaceuticals stocks. It's that simple.

How has Coronavirus impacted Ionis Pharmaceuticals's stock price?

Since the stock market crash in March caused by coronavirus, Ionis Pharmaceuticals's stock price has had significant negative movement.

Its last market close was $37.25, which is 38.42% down on its pre-crash value of $60.49 and 5.56% down on the lowest point reached during the March crash when the stocks fell as low as $39.32.

If you had bought $1,000 worth of Ionis Pharmaceuticals stocks at the start of February 2020, those stocks would have been worth $711.78 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $637.35.

Ionis Pharmaceuticals stock price

Use our graph to track the performance of IONS stocks over time.

Ionis Pharmaceuticals stocks at a glance

Information last updated 2021-07-22.
Latest market close$37.25
52-week range$34.43 - $64.37
50-day moving average $37.4789
200-day moving average $46.3451
Wall St. target price$57.83
Dividend yield N/A (0%)
Earnings per share (TTM) $0.518

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$4.99-$9.99
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$0
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$6.95
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are greater than or equal to US$10.00)
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95-$9.95
$9.95 + $1 per contract
$0
Free
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Ionis Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Ionis Pharmaceuticals price performance over time

Historical closes compared with the last close of $37.25

1 month (2021-06-25) -4.32%
3 months (2021-04-26) -14.62%

Is Ionis Pharmaceuticals under- or over-valued?

Valuing Ionis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ionis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ionis Pharmaceuticals's PEG ratio

Ionis Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 25.7033. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ionis Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Ionis Pharmaceuticals's EBITDA

Ionis Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$128.6 million.

The EBITDA is a measure of a Ionis Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Ionis Pharmaceuticals financials

Revenue TTM USD$707.5 million
Gross profit TTM USD$182.2 million
Return on assets TTM -3.9%
Return on equity TTM -46.8%
Profit margin -70.89%
Book value $4.829
Market capitalisation USD$5.3 billion

TTM: trailing 12 months

How to short and sell Ionis Pharmaceuticals stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "IONS.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 9.0 million Ionis Pharmaceuticals stocks held short by investors – that's known as Ionis Pharmaceuticals's "short interest". This figure is 0.4% up from 9.0 million last month.

There are a few different ways that this level of interest in shorting Ionis Pharmaceuticals stocks can be evaluated.

Ionis Pharmaceuticals's "short interest ratio" (SIR)

Ionis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Ionis Pharmaceuticals stocks currently shorted divided by the average quantity of Ionis Pharmaceuticals stocks traded daily (recently around 1.6 million). Ionis Pharmaceuticals's SIR currently stands at 5.57. In other words for every 100,000 Ionis Pharmaceuticals stocks traded daily on the market, roughly 5570 stocks are currently held short.

However Ionis Pharmaceuticals's short interest can also be evaluated against the total number of Ionis Pharmaceuticals stocks, or, against the total number of tradable Ionis Pharmaceuticals stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ionis Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding stocks (for every 100,000 Ionis Pharmaceuticals stocks in existence, roughly 60 stocks are currently held short) or 0.0672% of the tradable stocks (for every 100,000 tradable Ionis Pharmaceuticals stocks, roughly 67 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Ionis Pharmaceuticals.

Find out more about how you can short Ionis Pharmaceuticals stock.

Ionis Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Ionis Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Ionis Pharmaceuticals's total ESG risk score

Total ESG risk: 36.64

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Ionis Pharmaceuticals's overall score of 36.64 (as at 12/31/2018) is pretty weak – landing it in it in the 62nd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Ionis Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Ionis Pharmaceuticals's environmental score

Environmental score: 5.18/100

Ionis Pharmaceuticals's environmental score of 5.18 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Ionis Pharmaceuticals's social score

Social score: 26.17/100

Ionis Pharmaceuticals's social score of 26.17 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Ionis Pharmaceuticals's governance score

Governance score: 13.29/100

Ionis Pharmaceuticals's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Ionis Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Environmental, social, and governance (ESG) summary

Ionis Pharmaceuticals, Inc was last rated for ESG on: 2019-01-01.

Total ESG score 36.64
Total ESG percentile 62.18
Environmental score 5.18
Environmental score percentile 9
Social score 26.17
Social score percentile 9
Governance score 13.29
Governance score percentile 9

Ionis Pharmaceuticals stock dividends

We're not expecting Ionis Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Ionis Pharmaceuticals stock price volatility

Over the last 12 months, Ionis Pharmaceuticals's stocks have ranged in value from as little as $34.43 up to $64.37. A popular way to gauge a stock's volatility is its "beta".

IONS.US volatility(beta: 1.09)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ionis Pharmaceuticals's is 1.0865. This would suggest that Ionis Pharmaceuticals's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Ionis Pharmaceuticals overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Stocks similar to Ionis Pharmaceuticals

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site